Most Read Articles
12 Jun 2018
Percutaneous coronary intervention (PCI) is a safe procedure to perform on obese and morbidly obese patients, a recent study has shown.
Roshini Claire Anthony, 08 Jun 2018

Early treatment of superficial venous reflux (varicose veins) with endovenous ablation and compression therapy shortened healing time of venous leg ulcers compared with compression therapy either alone or in addition to delayed ablation, according to the EVRA* trial.

 

Beyond angina relief – Optimizing management of CAD with VASTAREL® MR®

08 Nov 2017
Available in Europe since 1978, trimetazidine was launched in Malaysia in 1986 as VASTAREL® 20, with the first box of this medication sold in 1987. At that time, this agent was available as three times daily dosing; this was soon followed by the modified-release formulation, ie, VASTAREL® MR®, launched in 2005 to simplify the dosing regimen. By 2007, VASTAREL® MR® had become widely available in public hospitals throughout Malaysia.The efficacy of trimetazidine in coronary artery disease (CAD) is well established – it is a well-tolerated anti-ischaemic agent with no effect on blood pressure or heart rate. It is also recommended by Malaysian and international guidelines for symptomatic relief of angina. In conjunction with the 30th anniversary of VASTAREL®, renowned local and international opinion leaders gathered at a Servier symposium, chaired by Dr Jeyamalar Rajadurai, to reflect on the evolution of CAD management and the contemporary role of trimetazidine.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Jun 2018
Percutaneous coronary intervention (PCI) is a safe procedure to perform on obese and morbidly obese patients, a recent study has shown.
Roshini Claire Anthony, 08 Jun 2018

Early treatment of superficial venous reflux (varicose veins) with endovenous ablation and compression therapy shortened healing time of venous leg ulcers compared with compression therapy either alone or in addition to delayed ablation, according to the EVRA* trial.